Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load, and outcomes.
about
Human cytomegalovirus resistance to antiviral drugsHow I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipientsGuidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspectiveThe clinical and financial burden of pre-emptive management of cytomegalovirus disease after allogeneic stem cell transplantation-implications for preventative treatment approaches.Diagnosis and management of human cytomegalovirus infection in the mother, fetus, and newborn infant.Quantification of cytomegalovirus glycoprotein Bn DNA in hematopoietic stem cell transplant recipients by real-time PCRPrevention and treatment of viral infections in stem cell transplant recipients.Induction of cytomegalovirus-specific T cell responses in healthy volunteers and allogeneic stem cell recipients using vaccination with messenger RNA-transfected dendritic cells.Management of acute graft-versus-host disease in children.Paradoxical rising cytomegalovirus antigenemia during preemptive ganciclovir therapy in hematopoietic stem cell transplant recipients: incidence, risk factors, and clinical outcomes.Human cytomegalovirus kinetics following institution of artesunate after hematopoietic stem cell transplantation.Management of infectious complications in the hematopoietic stem cell transplant recipient.Combating infections in hematopoietic stem cell transplant recipients.Cytomegalovirus following stem cell transplantation: from pharmacologic to immunologic therapy.Cytomegalovirus in hematopoietic stem cell transplant recipientsClinical Application of Variation in Replication Kinetics During Episodes of Post-transplant Cytomegalovirus Infections.Randomized Controlled Trials to Define Viral Load Thresholds for Cytomegalovirus Pre-Emptive Therapy.Novel decay dynamics revealed for virus-mediated drug activation in cytomegalovirus infection.Tailoring steroid-sensitive virus-specific T cells with TALENCosts of allogeneic hematopoietic cell transplantation with high-dose regimens.Effect of artemether-lumefantrine (Coartem) on cytomegalovirus urine viral load during and following treatment for malaria in children.Recent developments in human cytomegalovirus diagnosis.Immunologic special forces: anti-pathogen cytotoxic T-lymphocyte immunotherapy following hematopoietic stem cell transplantation.Comparison of DNA amplification, mRNA amplification, and DNA hybridization techniques for detection of cytomegalovirus in bone marrow transplant recipients.The genetic basis of human cytomegalovirus resistance and current trends in antiviral resistance analysis.Cytomegalovirus pneumonia in hematopoietic stem cell recipients.How we treat cytomegalovirus in hematopoietic cell transplant recipients.Comparison of quantitative cytomegalovirus real-time PCR in whole blood and pp65 antigenemia assay: clinical utility of CMV real-time PCR in hematopoietic stem cell transplant recipients.Diagnosis and treatment of viral diseases in recipients of allogeneic hematopoietic stem cell transplantation.Adoptive T cell immunotherapy for cytomegalovirus.The time is now: moving toward virus-specific T cells after allogeneic hematopoietic stem cell transplantation as the standard of care.The search for new therapies for human cytomegalovirus infections.Management of multidrug-resistant viruses in the immunocompromised host.Risk factors associated with elevated blood cytomegalovirus pp65 antigen levels in patients with autoimmune diseases.Therapeutic strategies for the prevention and treatment of cytomegalovirus infection.The immune response to cytomegalovirus in allogeneic hematopoietic stem cell transplant recipients.Outcomes in Transplant Recipients Treated With Foscarnet for Ganciclovir-Resistant or Refractory Cytomegalovirus InfectionImmunotherapy for transplantation-associated viral infections.Lack of emergence of cytomegalovirus UL97 mutations conferring ganciclovir (GCV) resistance following preemptive GCV therapy in allogeneic stem cell transplant recipients.Risk Factors and Utility of a Risk-Based Algorithm for Monitoring Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections in Pediatric Recipients after Allogeneic Hematopoietic Cell Transplantation.
P2860
Q24556634-0D7B8B4D-D1D2-48FF-B7A1-F0EE1C6A7BA8Q28069489-4491F21A-5875-407B-87E8-9F39BEAF5DCDQ28388806-94355C6E-B36D-481D-8CE0-31A2F5273CB3Q33734872-738A6D7F-A3C1-4B44-B101-C71FBFE3B310Q34102747-7203B358-408E-4C90-8742-5768DC22494EQ34516243-208482BB-565E-40E6-904D-3CD7EBC8731DQ34722706-55D08710-6081-4D6E-BC93-99B71F0FA8D3Q34796892-951437D9-80FF-441A-BB74-CEF189B0F42EQ35583009-9992BF9C-288C-4B0A-B7CD-04A27697EE6DQ35598906-0D616E56-59CC-4EC1-8ADA-07DA3E8E9C90Q35661025-47B8D996-A719-484C-81F1-D34286AFB175Q35675979-F3701BC2-C424-4D98-B463-476F8BCA8E56Q35917135-542A1CCC-61E5-4921-A10C-D9CC034FEE74Q35917480-85F18B74-865A-45E0-BF80-1FCB1CB7C66AQ35922928-FF76ABCC-DC46-42D5-B7D0-C00145E9E740Q35947524-0355969C-03FF-4580-ADE5-7E538B5F0A75Q36147994-EF1353F5-C44C-4C17-9DA3-8F132F45E494Q36346012-0F661F88-D73A-494B-A372-DC779BFB10E9Q36406966-9A20D5AD-86FF-406E-9498-A35ADAB7FD9BQ36485256-0B4A82C5-D010-41BE-9CBA-D6EF89B34888Q36689547-BDF49091-66D6-4AC8-B0C1-42AA4E60D9CCQ36839729-03381ED2-06B3-45E5-8662-3F33B9C6473DQ36956443-422868E5-253F-44EB-A563-71053FC0A2B1Q37059437-3221CAC4-A0A7-40C5-9074-9C6C98F76670Q37173390-0122A7CA-9EB2-4AEB-A8F4-89B199F50CF7Q37179131-B4C78C75-3391-49B8-AFB3-97956D22C4B4Q37237427-F9CEEADC-1BFC-4AD6-810D-69B1388FA28DQ37284695-502FEF89-FD34-4E6B-95B7-ED44670BA405Q37426542-E27D8C24-4925-4676-A04C-C6117CE9E9AFQ37489881-C2E11809-6D14-4CA7-A34F-84EE2B318894Q37592177-A4E76D1D-B996-4374-A8C1-5976BF1E3A50Q37811458-D09B6F65-B77A-4748-9C8F-4B7645C1F32DQ37970424-E76B7778-0D87-4142-A421-D78C79162DEAQ38005586-F5C687CE-809B-4B74-8220-E1419351FDB1Q38014916-4CFFC733-FBB7-4467-A828-1ADD52430837Q38547042-14EA7F09-7882-4AE9-B9BF-8821C4AC5E1BQ38834042-33672D75-EA08-43B0-B8F0-8858E04597B9Q39382670-30FA1C58-1339-4A19-9318-20C6F49F822FQ39479368-AC6195FB-D3B4-4099-966F-8ED3BD5E169FQ39716725-4FE4C06D-60A3-403B-B62A-86DC47A4960E
P2860
Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load, and outcomes.
description
2001 nî lūn-bûn
@nan
2001 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Rising pp65 antigenemia during ...... n with DNA load, and outcomes.
@ast
Rising pp65 antigenemia during ...... n with DNA load, and outcomes.
@en
type
label
Rising pp65 antigenemia during ...... n with DNA load, and outcomes.
@ast
Rising pp65 antigenemia during ...... n with DNA load, and outcomes.
@en
prefLabel
Rising pp65 antigenemia during ...... n with DNA load, and outcomes.
@ast
Rising pp65 antigenemia during ...... n with DNA load, and outcomes.
@en
P2093
P356
P1433
P1476
Rising pp65 antigenemia during ...... n with DNA load, and outcomes.
@en
P2093
Nichols WG
P304
P356
10.1182/BLOOD.V97.4.867
P407
P577
2001-02-01T00:00:00Z